| Followers | 66 |
| Posts | 4898 |
| Boards Moderated | 0 |
| Alias Born | 06/12/2014 |
Saturday, August 01, 2020 5:19:38 AM
Mrna+Bntx+pfe+curevac+own treatment=$,$$$,$$$,$$$
Also, during the first quarter, and under the direction of Arbutus’ Chief Scientific Officer, Dr. Michael Sofia, the Company has initiated an internal research program to identify new small molecule antiviral medicines to treat COVID-19 and future coronavirus outbreaks. Dr. Sofia, who was awarded the Lasker-DeBakey Award for his discovery of sofosbuvir, brings extensive antiviral drug discovery experience to this new program. Arbutus has also joined forces with the COVID R&D consortium to further support and expedite efforts to address the COVID-19 pandemic.
The establishment of the COVID-19 effort does not impact Arbutus’ current cash burn guidance for 2020 of $54 to $58 million.
626,000 shares $3.81 LOADED at 3:59 et just before the bell. $2,385,060 Million Dollars
https://twitter.com/StockRoomBully/status/1289382526595694593?s=19
While our core mission at Arbutus is to find a cure for hepatitis B, the magnitude of the coronavirus pandemic is undeniable.
Given our proven expertise in the discovery of new antiviral therapies, we feel compelled to work towards the discovery of a 5[color=red][/color]
To that end, we have assembled an internal team of expert scientists, with proven track records in bringing new antiviral medicines to market, to identify novel small molecule therapies to treat COVID-19.
We have also recently joined forces with the COVID R&D consortium to further support and expedite efforts to address the SARS-CoV-2 pandemic and any future coronavirus outbreaks.”
At this time, Arbutus’ COVID-19 research program will focus on the discovery and development of new molecular entities that address specific viral targets including the nsp12 viral polymerase and the viral protease. These targets are essential viral proteins which Arbutus has experience in targeting
This is getting INTERESTING SUPERNOVA. Not their 1st rodeo. Their very own treatment for covidsoon to be reveal
A-Team!
https://www.globenewswire.com/news-release/2020/05/11/2030868/0/en/Arbutus-Reports-First-Quarter-2020-Financial-Results-Provides-Pipeline-Update-and-Announces-New-Research-Initiative-to-Identify-Novel-Antiviral-Therapies-for-the-Treatment-of-Coron.html
Recent ABUS News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 08:01:33 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 09:29:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 11:31:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 11:31:16 AM
- Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/13/2026 11:30:00 AM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/28/2026 09:54:41 PM
- Arbutus Shares Jump After FDA Grants Fast Track Status to Hepatitis B Therapy • IH Market News • 04/15/2026 02:09:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 11:31:20 AM
- Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B • GlobeNewswire Inc. • 04/15/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/14/2026 09:05:20 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/14/2026 09:02:17 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/13/2026 11:56:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:31:10 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/23/2026 11:30:44 AM
- Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute • IH Market News • 03/04/2026 11:24:49 AM
- Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna • GlobeNewswire Inc. • 03/03/2026 09:15:00 PM
- Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna • GlobeNewswire Inc. • 03/03/2026 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 09:01:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 09:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:21:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:21:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2026 12:41:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2025 01:00:44 PM
